At Taj Pharma India Ltd., we position ourselves as a trusted pharmaceutical manufacturing, licensing, and development partner for regulated and semi-regulated markets worldwide. With a strong foundation in WHO-GMP compliant manufacturing, robust regulatory experience, and a diversified development pipeline, we actively engage in regional licensing, in-licensing, co-development, and commercialization partnerships across multiple therapeutic segments.

Product NameBrand NameTherapeutic CategoryDosage FormAvailable StrengthsBCS Class (Estimate)
BilastineBILATAJAnti-Allergic / AntihistamineTablet10 mg, 20 mgII
Diclofenac Sodium + ParacetamolDICLOTAJ-PAnalgesic / NSAIDTabletAs per labelII
EsomeprazoleESOTAJAnti-Ulcer / PPITablet20 mgII
EscitalopramESCITAJAntidepressant / SSRITablet10 mg, 20 mgI
Itopride HydrochlorideITOPRITAJGastroprokineticTablet50 mgIII
Micronized Purified Flavonoid Fraction (MPFF)FLAVOTAJVascular / VenotonicTablet500 mgIII
MoxonidineMOXONITAJAntihypertensiveTablet0.2 mgI
PancreatinPANCRETAJDigestive EnzymeCapsule / Tablet10,000 IU, 25,000 IUIII
RosuvastatinROSUTAJLipid-Lowering / StatinTablet10 mgII
TamsulosinTAMTAJUrology / BPHCapsule0.4 mgII
TretinoinTRETOTAJDermatology / Anti-AcneCream0.05% w/wIV
VenlafaxineVENLATAJAntidepressant / SNRITablet37.5 mg, 75 mg, 150 mgI
FebuxostatFEBUTAJAnti-GoutTablet80 mg, 120 mgII
Atomoxetine HydrochlorideATOMOXTAJADHD / CNSCapsule10 mg, 18 mg, 25 mg, 40 mg, 60 mgI

Our Unit-1 Sarigam facility stands as a core pillar of our global partnership strategy, supported by an expanding Unit-2 product grid that is carefully aligned with evolving international market demand. Together, these units enable us to deliver ready-to-license dossiers, near-term submissions, and advanced development programs with speed, quality, and long-term scalability.

Unit-1 Sarigam: Licensing & Partnership Grid Overview

ANDA-Approved and Near-Term Submission Dossiers

Unit-1 Sarigam hosts a mature portfolio of ANDA-approved and submission-ready dossiers, developed to meet stringent international regulatory expectations. Several products have already been initiated at the plant level, ensuring rapid tech transfer, validation, and commercialization for partners.

Our Unit-1 grid is ideally suited for:

  • Regional licensing and exclusive distribution
  • Co-development and joint regulatory submissions
  • Commercial manufacturing and long-term supply agreements

Each dossier is supported by robust CMC documentation, validated manufacturing processes, and scalable production capabilities, significantly reducing partner risk and time-to-market.


Strategic Expansion: Unit-2 Product Grid Development

Market-Driven Product Inclusion Model

In parallel with Unit-1 operations, we are actively evaluating additional product inclusions under Unit-2, guided by direct market interest, partner inquiries, and regional demand intelligence. This approach ensures that Unit-2 investments are commercially viable, demand-backed, and strategically aligned with partner growth plans.

We strongly encourage partners to share specific product interests, tender requirements, or pipeline gaps, enabling us to prioritize development that delivers mutual commercial advantage.


Priority Products Under Evaluation for Unit-2

We are currently inviting market interest and partnership discussions for the following priority molecules:

  • Bumetanide Tablets
  • Phenytoin Sodium Extended-Release Capsules
  • Ursodeoxycholic Acid Capsules
  • Valaciclovir Tablets

These products have been identified based on global prescribing relevance, lifecycle sustainability, and strong regulatory pathways, making them ideal candidates for mid- to long-term regional partnerships.


Unit-2 Product Grid Highlights

READY / ANDA-Approved Dossiers

Our Unit-2 grid already includes a robust basket of ANDA-approved and market-ready products, enabling immediate licensing and commercialization:

  • Gabapentin Capsules
  • Levetiracetam Tablets
  • Colestipol Tablets
  • Diclofenac Potassium Tablets
  • Tizanidine Capsules
  • Desipramine Tablets
  • Isosorbide Mononitrate Extended-Release Tablets
  • And multiple additional products across key therapy areas

These dossiers are backed by validated stability data, reproducible manufacturing processes, and scalable commercial batch capability, making them ideal for fast-track market entry.


Stability Charged – Dossiers Ready

Several high-value molecules have completed formulation development and stability charging, with dossiers ready for partner-driven submissions:

  • Pimozide Tablets
  • Avatrombopag Tablets
  • Bismuth Subcitrate + Metronidazole + Tetracycline Capsules
  • Oxaprozin Capsules
  • Pyridostigmine Tablets

These products are particularly attractive for partners seeking pipeline depth with reduced development timelines.


Dossiers Planned by Q1–Q2 2026

Our forward-looking development roadmap includes strategic molecules scheduled for dossier finalization by Q1–Q2 2026, ensuring continuity and long-term portfolio strength:

  • Brivaracetam Tablets
  • Edoxaban Tablets
  • Amlodipine + Atorvastatin Fixed-Dose Combinations
  • Mesalamine Delayed-Release Tablets

This planned pipeline reflects our commitment to cardiovascular, CNS, and gastroenterology segments with sustained global demand.


Advanced Development / Prototype Completed

Taj Pharma’s R&D ecosystem supports advanced development and prototype-completed programs across complex and high-value therapeutic areas, including:

  • Sacubitril + Valsartan
  • Rivaroxaban
  • Semaglutide (Oral)
  • Bempedoic Acid
  • Obeticholic Acid

These programs span CNS, cardiovascular, metabolic, gastrointestinal, renal, and rare disease segments, offering partners opportunities to enter premium and differentiated markets with strong lifecycle potential.


Literature-Stage and Early-Phase Pipeline

Our innovation-driven pipeline also includes literature-backed and early-phase molecules positioned for next-generation portfolio expansion:

  • Resmetirom
  • Cenobamate
  • Finerenone
  • Lumateperone
  • And other emerging global therapies

These assets are ideal for co-development, risk-sharing, and future-focused partnerships.


Flexible Partnership Models Tailored to Your Market

We offer customizable collaboration structures designed to align with partner strategy, regulatory capability, and commercial objectives:

  • Regional licensing and exclusive partnerships
  • In-licensing and portfolio expansion
  • CMO / CDMO manufacturing solutions
  • Profit-sharing and royalty-based commercialization models
  • Joint development and regulatory submission partnerships

Our approach is partner-centric, ensuring transparency, technical depth, and long-term value creation.


Why Partner with Taj Pharma India Ltd.

  • WHO-GMP compliant manufacturing infrastructure
  • Proven experience in regulated and emerging markets
  • Strong CMC, formulation, and scale-up expertise
  • Diverse therapy coverage with future-ready pipeline
  • Agile decision-making and partner-aligned development

We combine scientific rigor with commercial pragmatism, enabling partners to achieve sustainable growth with reduced execution risk.


Connect With Us for Strategic Discussions

We welcome discussions on specific product interests, regional opportunities, and ongoing inquiries. Our technical and business development teams are prepared to engage in confidential, solution-driven conversations and align development priorities with your market needs.

TAJ PHARMA INDIA LTD.
Plot No. 1019, Vill. Sarigam, G.I.D.C.,
Road No. 10, Dist. Valsad,
Gujarat, India – 396155

Plant Location: https://g.co/kgs/WrD9gQQ

For Assistance, Contact:
+91 90995 11459 / +91 99040 00567